Your search for dabigatran returned 43 results

Despite trend toward lower stroke risk with high dose

The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.

The increased number of post-marketing reports of bleeding associated with use of dabigatran seems to be an example of stimulated reporting and may not represent an increased bleeding risk.

Combining dabigatran with certain statin medications could raise the odds for major hemorrhage in patients with atrial fibrillation, according to a study published online in CMAJ, the journal of the Canadian Medical Association.

Dabigatran is associated with higher risks of major bleeding and gastrointestinal bleeding compared with warfarin, but patients taking dabigatran also have a reduced risk of intracranial bleeding compared with those taking warfarin, according to new research.

For patients with venous thromboembolism, extended treatment with dabigatran is noninferior to warfarin.

Compared with other DOACs, rivaroxaban linked to higher rates of GI bleeding overall and in an analysis restricted to patients with atrial fibrillation

Efficacy similar to aspirin for preventing recurrent stroke after embolic stroke of undetermined source

Linked to lower risk of intracranial bleeding, but higher risk of gastrointestinal bleeding

Researchers performed a retrospective cohort study to compare incidence of stroke, bleeding, and myocardial infarction in patients with atrial fibrillation initiating dabigatran or warfarin (n=25,289 for each) from November 2010 to May 2014.